Chief Executive Officer

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Institution	Shares	Value	Change
Jupiter Topco	3,421,374	$1.1B	NEW
Vanguard	2,800,437	$938M	INCREASED
FMR	2,316,907	$776M	INCREASED
BlackRock	2,292,585	$768M	DECREASED
Perceptive Advisors	2,035,986	$682M	UNCHANGED

Insider	Type	Shares	Value	Date
Marcio Souza (Chief Executive Officer)	GIFT	2,600		2026-07-08
Marcio Souza (Chief Executive Officer)	GIFT	20,521		2026-07-08

Member	Type	Amount	Date
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-07-30
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-07-29

Praxis Precision Medicines, Inc. Common Stock (PRAX) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades